Olmesartan Medoxomil Accord

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil Accord, is a Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil Accord belongs to the class of Angiotensin II receptor blockers used to manage high blood pressure. - Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events in patients with elevated blood pressure.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing. - Hyperkalemia: elevated potassium levels that can affect heart rhythm. - Acute renal impairment: sudden decrease in kidney function. - Severe hypotension: marked drop in blood pressure causing faintness or shock.

Before initiating therapy, consider the following precautions: - Renal function monitoring: assess serum creatinine and eGFR periodically. - Serum potassium monitoring: check potassium levels, especially when combined with potassium‑sparing agents. - Pregnancy avoidance: contraindicated in pregnancy (Category D) due to fetal risk. - Elderly caution: start at lower doses and monitor for orthostatic hypotension. - Drug interaction awareness: avoid concomitant use with aliskiren in diabetic patients. - Store at room temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Olmesartan Medoxomil may interact with several medicines. Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction and hyperkalemia. - Dual blockade with ACE inhibitors or other ARBs: heightened risk of hypotension, hyperkalemia, and renal impairment. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and affect renal function. - Lithium: may raise lithium concentrations, risking toxicity. - Thiazide or loop diuretics: may enhance antihypertensive response and affect electrolyte balance.